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Although early and appropriate antibiotic therapy remains the most important intervention for successful treatment
of septic shock, data guiding optimization of beta-lactam prescription in critically ill patients prescribed with
continuous renal replacement therapy (CRRT) are still limited. Being small hydrophilic molecules, beta-lactams are
likely to be cleared by CRRT to a significant extent. As a result, additional variability may be introduced to the per se
variable antibiotic concentrations in critically ill patients. This article aims to describe the current clinical scenario for
beta-lactam dosing in critically ill patients with septic shock and CRRT, to highlight the sources of variability among
the different studies that reduce extrapolation to clinical practice, and to identify the opportunities for future research
and improvement in this field. Three frequently prescribed beta-lactams (meropenem, piperacillin and ceftriaxone)
were chosen for review. Our findings showed that present dosing recommendations are based on studies with
drawbacks limiting their applicability in the clinical setting. In general, current antibiotic dosing regimens for CRRT
follow a one-size-fits-all fashion despite emerging clinical data suggesting that drug clearance is partially dependent
on CRRT modality and intensity. Moreover, some studies pool data from heterogeneous populations with CRRT that
may exhibit different pharmacokinetics (for example, admission diagnoses different to septic shock, such as trauma),
which also limit their extrapolation to critically ill patients with septic shock. Finally, there is still no consensus regarding
the %T>MIC (percentage of dosing interval when concentration of the antibiotic is above the minimum inhibitory
concentration of the pathogen) value that should be chosen as the pharmacodynamic target for antibiotic therapy
in patients with septic shock and CRRT. For empirically optimized dosing, during the first day a loading dose is
required to compensate the increased volume of distribution, regardless of impaired organ function. An additional
loading dose may be required when CRRT is initiated due to steady-state equilibrium breakage driven by clearance
variation. From day 2, dosing must be adjusted to CRRT settings and residual renal function. Therapeutic drug
monitoring of beta-lactams may be regarded as a useful tool to daily individualize dosing and to ensure optimal
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Optimal antibiotic dosing in the ICU is still a controversial
issue that clinicians face daily. Despite compelling evi-
dence supporting early and appropriate antibiotic therapy
as one of the most effective interventions for improving
patient outcome [1], antibiotic selection and dosing is
often challenging in critically ill patients because of disease
complexity, resulting physiological alterations, and re-
duced antibiotic susceptibilities of nosocomial pathogens.
Besides, selecting an antimicrobial to which the causal
agent is susceptible is not sufficient to achieve the best
clinical outcomes, and factors such as adequate tissue
penetration and achievement of a pharmacodynamic target
associated with therapeutic success according to the anti-
biotic class are crucial for improving infection cure and
patient morbi-mortality [2-4].
Beta-lactam antibiotics are time-dependent antibiotics,
meaning that they exhibit optimal killing activity when
plasma concentrations are maintained above the minimum
inhibitory concentration of the bacteria during a percentage
of the dosing interval (%T>MIC). Beta-lactams are also the
most prescribed antibiotics in the ICU [5]. Significant and
unpredictable pharmacokinetic variability of this pharma-
cological group has been well documented in critically ill
patients: the volume of distribution (Vd) and the clearance
(CL) of beta-lactams have been found to vary significantly
depending on patient severity, proteinemia and organ fail-
ure, among other factors [3,6]. Acute kidney injury and the
requirement of continuous renal replacement therapy
(CRRT) add further variability to beta-lactam CL. However,
available clinical evidence supporting beta-lactam dosing in
critically ill patients with septic shock and CRRT is not yet
optimal, since recommendations are mainly elucidated
from healthy volunteers’ data and from clinical studies with
important patient variability and limited sample sizes.
The aims of this article are to describe the current clin-
ical scenario of beta-lactam dosing in critically ill patients
with septic shock and CRRT, to highlight the sources of
variability among the different studies that reduce extrapo-
lation to clinical practice, and to identify the opportunities
for future research and improvement in this field. For this
purpose, two of the most frequently prescribed beta-
lactams for nosocomial infections (meropenem and pi-
peracillin) and a highly protein-bound antibiotic usually
prescribed for community-acquired infections (ceftriaxone)
were chosen for a thorough review. A systematic review of
all available data on beta-lactam antibiotic pharmaco-
kinetics in critically ill patients with CRRT was beyond the
scope of this article, as this has been done elsewhere [7-9].
Search strategy and selection criteria
Data for this review were identified by systematic searches
of PubMed (1966 to November 2013), as well as refe-
rences cited by relevant articles. Search terms includedwere ‘meropenem’ or ‘piperacillin’ or ‘ceftriaxone’, ‘critically
ill patient’ or ‘intensive care unit’ or ‘critical illness’,
‘continuous veno-venous hemodiafiltration’ or ‘continuous
veno-venous hemodialysis’ or ‘continuous veno-venous
hemofiltration’ or ‘continuous renal replacement therapy’,
and ‘pharmacokinetics’ or ‘pharmacodynamics’. Relevant
articles written in English, Spanish and Catalan where
considered for this review. Those articles describing the
pharmacokinetics of meropenem, piperacillin/tazobactam
and ceftriaxone in adult critically ill patients receiving
CRRT were included.
Effect of septic shock and CRRT in antibiotic
dosing optimization
Classically, the in vitro susceptibility of the causal patho-
gen has been the cornerstone of antibiotic prescription.
However, selection according to susceptibility is only a
component of the optimal antibiotic therapy, and many
other factors must also be considered. In terms of poso-
logy, it is paramount to design dosing strategies that
maximize the likelihood of attaining the pharmacodynamic
target associated with therapy success in the biophase.
This is complex in the critically ill patient with septic
shock and CRRT since it is well known that critical sick-
ness and clinical interventions can drive to physiological
changes likely to alter drug pharmacokinetics [3] and
therefore likely to compromise the attainment of these
pharmacodynamic targets.
There are two important time periods that must be
considered for antibiotic dosing. The first period corre-
sponds to the first day of therapy, where the main deter-
minant for dosing must be the Vd since this determines
the early attainment of antibiotic concentrations within
the therapeutic range. In critically ill patients with sepsis,
increased Vd must be expected for hydrophilic anti-
biotics such as beta-lactams (see Tables 1, 2, 3, 4, 5 and 6),
aminoglycosides and glycopeptides [10-38]. This increase
may be due to the presence of bacterial endotoxins in the
bloodstream, which has a cascade effect on the production
of endogenous molecules that act on the vascular endothe-
lium, leading to vasodilation and transcapillary leakage of
fluid and proteins into the extracellular space, where these
antibiotics distribute. When the Vd is abnormally in-
creased, distribution of hydrophilic antibiotics such as
beta-lactams becomes more extensive for trying to com-
pensate this larger space, with greater movement of the
drug molecules from the central compartment (blood-
stream) to the peripheral compartments (mainly extravas-
cular fluid). The amount of the drug in plasma
consequently decreases, and therefore the plasma concen-
tration decreases. Consequently, given a particular mini-
mum inhibitory concentration, shorter %T>MIC values can
be expected, which in turn may compromise beta-lactams’
pharmacodynamic target attainment [39]. Critically ill
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1 Critically ill patient
with septic shock
and AKI





every 12 hours for
three doses then
1 g every 8 hours
AN 69 HF, type of
membrane N/R
CVVHDF QD: 0.75 l/
hour, QR:
1.25 l/hour
The table includes healthy volunteers’ data with comparative purpose. AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; BSAC,
British Society for Antimicrobial Chemotherapy; CI, continuous infusion; CrCL, creatinine clearance; CRRT, continuous renal replacement therapy; CVVHDF,
continuous venovenous hemodiafiltration; CVVHF, continuous venovenous hemofiltration; EUCAST, European Committee on Antimicrobial Susceptibility Testing;
MIC, minimum inhibitory concentration; MODS, multiple organ dysfunction syndrome; N/A, not applicable; NCCLS, National Committee of Clinical Laboratory
Standards; N/R, not reported; QD, dialysis fluid flow rate; QR, replacement fluid flow rate; RRT, renal replacement therapy; SOFA, Sequential Organ Failure
Assessment; %T>MIC, percentage of dosing interval while concentration of the antibiotic is above the minimum inhibitory concentration of the pathogen.
aData
presented as mean ± standard deviation or median (interquartile range).
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beta-lactam antibiotics during the first 24 to 48 hours,
regardless of organ function, in order to compensate the
increased Vd and to reach concentrations within the
therapeutic range on the first day of therapy [39].
The particular case of CRRT requirement poses another
scenario where loading doses may be considered. At the
time of CRRT initiation, antibiotic concentrations over
time are in steady-state equilibrium (if the antibiotic was
initiated before CRRT commencement), but one can
hypothesize that the change in drug CL induced by CRRT
initiation may lead to the breakage of this equilibrium and,consequently, to a decrease in drug concentrations. A new
steady state will follow after seven half-lives since the
introduction of the foreign source of drug CL. During this
time period, however, concentrations may fall below the
therapeutic range. At this point, an additional loading dose
may help in the maintenance of therapeutic levels. This
phenomenon of steady-state breakage follows the theo-
retical pharmacokinetics principles but there are no stu-
dies yet that describe it in critically ill patients and hence
concrete loading dose recommendations cannot be pro-
vided. Certainly this is a very interesting area that deserves
further research to be properly understood.
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1 g every 12 hours Case report with
limited comparability
to other studies
The table includes healthy volunteers’ data with comparative purpose. CI, continuous infusion; CL, clearance; CrCL, creatinine clearance; CRRT, continuous renal
replacement therapy; CV, coefficient of variation; CVVHDF, continuous venovenous hemodiafiltration; CVVHF, continuous venovenous hemofiltration; MIC,
minimum inhibitory concentration; N/A, not applicable; N/R, not reported; QD, dialysis fluid flow rate; Vd, volume of distribution.
aData presented as mean ±
standard deviation or median (25 to 75 % range).
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Table 3 Available data on piperacillin pharmacokinetics in continuous renal replacement therapy
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10 Critically ill patients
with severe sepsis/
septic shock and
AKI. APACHE II 33
(31 to 36), SOFA 12
(10 to 15)
N/R Target: 50 % T>MIC
for clinically
relevant MIC (2, 4,









AN 69 HF, 1.05 m2
polyacrylonitrile
filter
CVVHDF QD: 1 to 1.5 l/hour,
QR: 1.5 to 2 l/hour, QT:
3.0 to 3.9 l/hour
The table includes healthy volunteers’ data with comparative purpose. AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; BSAC,
British Society for Antimicrobial Chemotherapy; CAVHD, continuous arteriovenous hemodialysis; CCF, Cleveland Clinic Foundation; CI, continuous infusion; CLSI:
Clinical and Laboratory Standards Institute; CrCL, creatinine clearance; CRRT, continuous renal replacement therapy; CVVHD, continuous venovenous hemodialysis;
CVVHDF, continuous venovenous hemodiafiltration; CVVHF, continuous venovenous hemofiltration; EUCAST, European Committee on Antimicrobial Susceptibility
Testing; MIC, minimum inhibitory concentration; MODS, multiple organ dysfunction syndrome; N/A, not applicable; N/R, not reported; QD, dialysis fluid flow rate;
QR, replacement fluid flow rate; QT, total flow rate; RRT, renal replacement therapy; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure
Assessment; %T>MIC, percentage of dosing interval while concentration of the antibiotic is above the minimum inhibitory concentration of the pathogen; VAP,
ventilator-associated pneumonia. aData presented as mean ± standard deviation or median (interquartile range).
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period, the estimated drug CL is the main determinant
of dosing, with the objective of maintaining the equilib-
rium between input and output as the tissues should
already hold therapeutic antibiotic concentrations. In
this context, CRRT represents a particular challenge in
terms of dosing, especially for hydrophilic antibiotics, as
concentrations may vary depending on the degree of ex-
traction, which in turn depends on the CRRT modality,
on drug physicochemistry and, presumably, on CRRT
intensity [7]. Moreover, residual renal function is usu-
ally variable, difficult to assess and rarely considered
when dosing, despite its relevant contribution to anti-
biotic CL in patients undergoing CRRT that has been
described for meropenem and piperacillin among
others [26,29,32]. Finally, the patient’s condition
evolves throughout the ICU stay so the influence of
the previously mentioned factors may vary over time,
making it difficult to generalize recommendations only
based on CRRT modality and intensity. Dosing shouldideally be titrated daily depending on the CRRT set-
tings and the evolution of the patient’s renal function.
With this aim, therapeutic drug monitoring (TDM) of
trough levels might be a useful tool for refining dosing
decisions during the maintenance phase of therapy, as
it is routinely performed with aminoglycosides and gly-
copeptides. However, despite emerging data suggesting
that beta-lactam TDM might improve the attainment
of pharmacodynamic targets associated with thera-
peutic success [40], the impact of systematic TDM on
clinical outcomes and resource use is still to be pro-
spectively validated. Due to the variable pharma-
cokinetics of these drugs in critically ill patients with
CRRT, TDM certainly deserves further investigation.
Determinants of drug clearance by CRRT
Among the many options for renal replacement, CRRT
is the most used in the critical care setting due to its ad-
vantages in hemodynamically unstable patients com-
pared with intermittent techniques [41]. Drug clearance
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Table 4 Available data on piperacillin pharmacokinetics in continuous renal replacement therapy (Continued)
for MIC = 64 mg/l
(total piperacillin),
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to 13.2)






































































































Survival N/R, 100 %
target attainment






No site of infection
and survival
reported
The table includes healthy volunteers’ data with comparative purpose. CI, continuous infusion; CL, clearance; CrCL, creatinine clearance; CRRT, continuous renal
replacement therapy; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous hemodiafiltration; CVVHF, continuous venovenous
hemofiltration; IQR, interquartile range; MIC, minimum inhibitory concentration; N/A, not applicable; N/R, not reported; PTA, probability of target attainment; S/R,
sensitive/resistant; Vd, volume of distribution. aData presented as mean ± standard deviation or median (25 to 75 % range).
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drug characteristics and CRRT modality and intensity.
Continuous venovenous hemodialysis is based on the
principle of diffusion of solutes across a semipermeable
membrane driven by a concentration gradient, while
continuous venovenous hemofiltration clearance is
driven mainly by convection removal, where a positive
hydrostatic pressure drives water and solutes across the
filter membrane from the blood compartment to the fil-
trate compartment, from which it is drained. Continuous
venovenous hemodiafiltration is the most efficienttechnique for solute removal, consisting of a combin-
ation between the two abovementioned techniques and
resulting in the removal of hydrophilic solutes with sim-
ultaneous water elimination [7].
Regardless of the modality prescribed, a common de-
terminant of drug clearance in CRRT is protein binding.
Due to protein size and electrical charge, protein-bound
molecules are unable to pass through the filter mem-
branes and only unbound molecules will be available for
elimination by CRRT. This is so critical that both sieving
coefficients and saturation coefficients are usually
Table 5 Available data on ceftriaxone pharmacokinetics in hemofiltration
Study n Population and scorea Site of
infection
















54 Critically ill patients with
sepsis, severe sepsis or septic
shock with various degrees
of renal function, 12 with








pneumoniae) to 8 mg/dl
(Staphylococcus aureus)
Ceftriaxone 2 g every
24 hours (41 cases), 1 g every
24 hours (one case), 2 g
every 12 hours (one case)






6 Critically ill patients with
sepsis and AKI








The table includes healthy volunteers’ data with comparative purpose. AKI, acute kidney injury; CRRT, continuous renal replacement therapy; CVVHF, continuous
venovenous hemofiltration; MIC, minimum inhibitory concentration; N/A, not applicable; N/R, not reported; QR, replacement fluid flow rate; RRT, renal replacement
therapy; SAPS, Simplified Acute Physiology Score; %T>MIC, percentage of dosing interval while concentration of the antibiotic is above the minimum inhibitory
concentration of the pathogen. aData presented as mean ± standard deviation or median (interquartile range).
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biotic protein-binding alterations have been broadly ob-
served in ICU patients [6] due to the altered plasmatic
protein homeostasis associated with critical illness (the
SAFE study reported that 40 to 50 % of the ICU patients
had albumins <25 g/l) [42] and due to the presence of
other highly protein-bound exogenous drugs and en-
dogenous molecules (such as bilirubin) in plasma. This
may consequently translate into alterations in the extent
to which an antibiotic is cleared by CRRT. However,
whereas the effect of hypoalbuminemia on antibiotic
pharmacokinetics in critically ill patients with preserved
renal function has been documented in previous studies
[6], there are no available studies regarding its combined





















































The table includes healthy volunteers’ data with comparative purpose. CL, clearance
replacement therapy; %T>MIC, percentage of dosing interval while concentration of
Vd, volume of distribution. aData presented as mean ± standard deviation or mediaAnother factor likely to affect the extent to which
drugs are cleared by CRRT is the CRRT intensity. The
question of what is the optimal CRRT intensity has been
a controversial issue since its first implantation. Several
studies have evaluated the impact of using different
CRRT intensities on mortality and recovery of renal
function in critically ill patients, with different, usually
debatable, results [43-48]. Due to this lack of definitive
evidence, current clinical recommendations define the
area of best practice for CRRT intensity as lying between
20 and 40 ml/kg/hour [41], the clinician being respon-
sible for individualizing the appropriate CRRT intensity
for each particular patient. However, the impact of dif-
ferent CRRT intensities on antibiotic dosing require-

















No report of severity scores, RRT
settings, residual diuresis and CrCL
estimation method, unbound






No residual diuresis and CrCL
estimation method reported. No
outcomes study performed, no
septic shock, no albumin
concentrations considered
; CrCL, creatinine clearance; N/A, not applicable; N/R, not reported; RRT, renal
the antibiotic is above the minimum inhibitory concentration of the pathogen;
n (25 to 75 % range).
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ability in drug CL by CRRT may be introduced by
medical devices that may coexist with CRRT in patients
with septic shock, such as polymyxin B fiber columns
(to reduce endotoxin levels in sepsis) or extracorporeal
membrane oxygenation. Other factors such as filter
lifespan, filter anticoagulants such as citrate and drug
recirculation may also have an effect on drug CL.
However, their potential for antibiotic adsorption and
removal has not yet been estimated.
Main limitations of available pharmacokinetic
studies
To discuss the current scenario of beta-lactam dosing in
patients with septic shock and CRRT, we performed a
thorough review of the existing clinical data for three of
the most frequently used (and studied) beta-lactam anti-
biotics in the ICU. Tables 1, 2, 3, 4, 5 and 6 summarize the
available evidence on meropenem, piperacillin/tazobactam
and ceftriaxone pharmacokinetics in critically ill patients
with CRRT [15-38,49,50].
Critical review of these studies has lead to identifica-
tion of the following points that limit applicability of
dose recommendations to critically ill patients with sep-
tic shock and CRRT.
Patient population
The identified studies handle a highly heterogeneous
patient population, which may jeopardize the generalizability
of the results. For example, there are studies that pool to-
gether patients with septic shock and cardiogenic shock
[17,31]. The physiopathology of these two types of shock,
however, is very different: septic shock is caused by peri-
pheral vasodilation, systemic inflammation and, consequently,
increased Vd; while cardiogenic shock involves peripheral
vasoconstriction, which should have no effect on the Vd.
Other studies include septic and polytrauma patients
requiring CRRT [25,32]. Of note, one of these studies
overcame the admission diagnosis-driven variability by
developing a population pharmacokinetics model. The
investigators found that admission diagnosis significantly
influenced pharmacokinetic parameters: trauma patients
exhibited higher Vd and CL than septic patients (d =
69.5 and 15.7 l in trauma patients and septic patients,
respectively; CL = 54.15 and 8.04 l/hour in trauma pa-
tients and septic patients, respectively) [25]. Patients
with sepsis/severe sepsis may also substantially differ
from patients with septic shock: septic shock patients
may exhibit higher Vd due to capillary leakage and ag-
gressive fluid resuscitation as compared with critically ill
patients without septic shock. In spite of this, some of
the available studies include patients with sepsis/severe
sepsis and acute kidney injury [21,33-35,37,49,50] but
not those with septic shock.Furthermore, a significant number of the articles do
not report clinical severity scores for the studied popula-
tion. In particular, increasing Acute Physiology and
Chronic Health Evaluation II scores have been shown to
correlate with increased Vd for hydrophilic antibiotics
such as aminoglycosides [12]. However, variations in the
Vd of meropenem and piperacillin have been reported in
the literature (see Tables 1, 2, 3, 4 and 5). Similarly,
CRRT may be prescribed in patients who still present a
significant residual renal function. The influence of re-
sidual renal function on piperacillin pharmacokinetics in
patients receiving continuous venovenous hemofiltration
has been assessed by Arzuaga and colleagues, and sig-
nificant differences in piperacillin CL have been re-
ported; for example, total drug CL in patients with
creatinine CL > 50 ml/minute was tripled as compared
with patients with creatinine CL < 10 ml/minute [51].
These points suggest that the one-size-fits-all dosing
recommendations based only on CRRT prescription may
not apply to all different types of critically ill patients, as
they are a highly heterogeneous population that may
require different doses.
Continuous renal replacement therapy modality and flow
rate
Regarding CRRT modalities, there is discordance in the
literature on whether a specific modality makes a diffe-
rence or not in terms of dosing. While some studies sup-
port a difference in CL partially due to CRRT modality
[49,50], some others suggest that there are no substantial
variations between modalities [22]. Theoretically, con-
vective and diffusive methods eliminate molecules from
the bloodstream using different processes, and therefore
the total drug CL should differ between CRRT moda-
lities, as has been shown with piperacillin and meropenem
[49,50], but a significant volume of dosing recommenda-
tions are still generic for CRRT.
Regarding CRRT intensity, emerging evidence suggests
that the total flow rate affects the CL of hydrophilic
drugs with low protein binding. For example, Beumier
and colleagues developed a population pharmacokinetics
model for vancomycin administered as a continuous in-
fusion in critically ill patients with sepsis and septic
shock, and found that inclusion of CRRT intensity as a
covariate on CL significantly improved the model [52].
Similarly, a study by Bilgrami and colleagues specifically
targeted patients with high-intensity CRRT (>4 l/hour)
receiving meropenem and found that total drug CL was
higher compared with previous studies with lower inten-
sity CRRT, intensity being the main parameter that
accounted for the differences in meropenem CL (R2 =
0.89) [15]. The high CRRT intensity was such a deter-
minant of meropenem CL that the doses required for
the coverage of less susceptible bacteria (minimum
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used in patients without renal failure (1,000 mg every
8 hours). These data suggest that different CRRT inten-
sities may translate into different drug CL and therefore
into different dose requirements. Importantly, one must
also highlight that most of the published studies use
CRRT intensities in the lower range of the area of best
practice (1 to 2 l/hour; 14.3 to 28.5 ml/kg/hour for a
70 kg adult) [16,17,19-21,27,29,30,32,34,35,49,50], while
the actual tendency in the clinical setting may be using
CRRT intensities in the higher range (>30 ml/kg/hour),
especially for septic patients [41,46]. In fact, a recent
study by Varghese and colleagues studied the pharmaco-
kinetics of piperacillin/tazobactam in critically ill pa-
tients with anuria/oliguria and CRRT at a median
intensity of 38.5 ml/kg/hour, and reported higher drug
CL (median 5.1 (interquartile range 4.2 to 6.2) l/hour)
compared with other studies that used lower CRRT in-
tensities (see Table 3 and 4) [38].
Moreover, the methodology for the calculation of
CRRT intensity is not defined in most of the studies.
Some of the studies report that an absolute CRRT inten-
sity was prescribed to all patients, without being norma-
lized to body weight. This leads to inherently variable
CRRT doses, inversely proportional to the actual pa-
tient’s weight. For instance, an absolute CRRT intensity
of 2 l/hour for a 100 kg patient results in a relative flow
rate of 20 ml/kg/hour, whereas for a 50 kg patient the
rate is 40 ml/kg/hour. When relative flow rate is pre-
scribed, clinicians usually use body weight previous to
admission or ideal body weight, and calculate the flow
rate using the following formula:
Flow rate ¼ QD þ QRð Þ=weight kgð Þ
where QD is the dialysis fluid flow rate (ml/hour) and
QR is the replacement fluid flow rate (ml/hour).
The rationale of this methodology is to avoid varia-
tions in the calculated flow rate over time as the pa-
tient real weight fluctuates during the ICU stay (for
example, due to fluid therapy or edema) [53]. How-
ever, most of the studies do not report how body
weight was considered in spite of the fact that it is es-
sential to know which CRRT intensity was prescribed
[43]. When real body weight is used, the calculated
flow rate may be falsely low, as the denominator in
the equation usually increases during the ICU stay.
Recommendations include application of body weight
previous to admission or ideal body weight [43]. How-
ever, considering the increasing prevalence of obesity
in developed countries, one should discuss whether
ideal body weight or body weight previous to admis-
sion should be used.Pharmacodynamic target for dosing recommendations
Antibiotic dosing recommendations intend to achieve a
pharmacodynamic target that, for beta-lactams, is de-
fined by the %T>MIC value [54]. Classical studies report
that penicillins and monobactams require at least a 50
to 60 % T>MIC for maximal bactericidal activity, cephalo-
sporins require a 60 to 70 % T>MIC and carbapenems re-
quire a 40 % T>MIC [54]. However, most of these
recommendations are based on in vitro studies and on
animal models of bacteremia, where penetration into the
site of infection is not considered. In vivo, higher %
T>MIC values in plasma may be needed for achieving the
abovementioned targets in biophases other than the
bloodstream, since penetration into the target site fol-
lows diffusion kinetics and depends on the physicochem-
istry of each particular tissue. For instance, Roberts and
colleagues reported that continuous infusion of full
doses of meropenem (that is, 100 % T>MIC in plasma)
was required for achieving 40 % T>MIC for less suscep-
tible pathogens in subcutaneous tissue [11]. Also, the at-
tainment of a particular percentage of T>MIC may be
modified by the susceptibility cutoff values for the differ-
ent bacteria, which vary depending on the country where
the study is performed (for example, European Commit-
tee on Antimicrobial Susceptibility Testing vs Clinical
and Laboratory Standards Institute breakpoints). The
recommendations based upon a particular minimum in-
hibitory concentration in Europe may therefore not
apply to the United States of America and vice versa.
Critical review of clinical pharmacokinetics data leads
to the final consideration that there are multiple missed
opportunities in the available literature. Further studies
should be more focused on the study population of crit-
ically ill patients with septic shock in order to avoid vari-
ability derived from pathophysiological conditions other
than septic shock. Inclusion and exclusion criteria
should therefore carefully evaluate the admission diag-
nosis and the patient condition during the study period.
Also, a population pharmacokinetics approach would be
preferred to the noncompartmental approach, since the
noncompartmental approach draws inaccurate conclu-
sions because covariates that have an effect on para-
meter variability cannot be identified. Finally, consensus
regarding clinical pharmacodynamic targets for beta-
lactams would be helpful in the unification of dosing
recommendations.
Conclusions
Optimization of beta-lactam therapy in CRRT is com-
plex and is dependent on several drug, CRRT and
patient-related factors. Consideration of drug physico-
chemistry and protein binding, CRRT settings and
disease-related pharmacokinetic alterations is essential
for individualizing dose regimens with the purpose of
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success.
During the first day, an initial loading dose is required
to achieve drug concentrations within the therapeutic
range early in time, regardless of impaired organ func-
tion. This principle may also apply to the moment of
CRRT commencement, where a loading dose may be re-
quired to maintain concentrations within the therapeutic
range. From day 2, dosing must be adjusted to CRRT
settings and residual renal function. The complexity of
dosing occurs due to the great variability encountered.
As such, TDM of trough levels of beta-lactams may be
regarded as a promising and key tool to individualize
dosing daily and to ensure optimal exposure to the
antibiotic.
Current dose recommendations are based on studies
with some drawbacks that limit their applicability to the
current clinical scenario. Mainly, dosing recommenda-
tions in CRRT follow a one-size-fits-all fashion, despite
emerging clinical data suggesting that beta-lactam CL is
partially dependent on CRRT modality and intensity.
Moreover, heterogeneous populations have been pooled
in the studies, limiting extrapolation to critically ill pa-
tients with septic shock and CRRT. Finally, there is still
some controversy on the %T>MIC value that must be
chosen as the pharmacodynamic target associated with
success for tailoring dosing recommendations.
Further research on dose adjustment of beta-lactam
antibiotics in critically ill patients with septic shock and
CRRT is required in order to establish reliable and up-
to-date recommendations that ensure optimal therapy
and thus increase the likelihood of optimal outcomes in
this population.
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